Radionetics Oncology

📍 San Diego, United States🗓 Founded 2021👥 39 employees💰 Last funded Jun 2024
Pharmaceutical Manufacturing🌐 radionetics.com
Website LinkedIn
Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company focused on the discovery and development of novel radiopharmaceuticals for the treatment of a wide range of oncology indications and is poised to capitalize on the increasing demand for novel radiotherapeutics. Radionetics Oncology is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments and has entered into a strategic agreement with Eli Lilly. Radionetics is advancing a pipeline of first-in-class small molecule radioligands targeting G protein coupled receptors for the treatment of a broad range of cancers, including breast cancer, lung cancer, and other indications of high unmet need.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Radionetics Oncology?
Radionetics Oncology has 1 investors on record on gritt.io, 1 mid-stage.
When did Radionetics Oncology last raise funding?
The most recent investment in Radionetics Oncology recorded on gritt.io was in June 2024.
When was Radionetics Oncology founded?
Radionetics Oncology was founded in 2021.
What industry is Radionetics Oncology in?
Radionetics Oncology operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Radionetics Oncology based?
Radionetics Oncology is headquartered in San Diego, United States.